Elicera Therapeutics AB (publ) (FRA:8E8)

Elicera Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Other Revenue	10.86	7.13	11.23	1.28	0
Revenue	10.86	7.13	11.23	1.28	0
Revenue Growth (YoY)	52.28%	-36.52%	777.23%	217987.39%	-
Gross Profit	10.86	7.13	11.23	1.28	0
Selling, General & Admin	28.8	24	28.31	20.63	13.11
Operating Expenses	28.8	24.01	28.33	20.64	13.12
Operating Income	-17.94	-16.88	-17.1	-19.36	-13.12
Interest Expense	-0.01	-0.05	-0.08	-0.13	-0
Interest & Investment Income	0.55	0.83	0.77	0.05	-
Other Non Operating Income (Expenses)	-	0	-	-	0
EBT Excluding Unusual Items	-17.41	-16.11	-16.4	-19.44	-13.12
Pretax Income	-17.41	-16.11	-16.4	-19.44	-13.12
Net Income	-17.41	-16.11	-16.4	-19.44	-13.12
Net Income to Common	-17.41	-16.11	-16.4	-19.44	-13.12
Shares Outstanding (Basic)	46	32	20	20	16
Shares Outstanding (Diluted)	46	32	20	20	16
Shares Change (YoY)	44.30%	59.89%	-0.40%	23.97%	32.98%
EPS (Basic)	-0.38	-0.51	-0.83	-0.98	-0.82
EPS (Diluted)	-0.38	-0.51	-0.83	-0.98	-0.82
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-165.31%	-236.86%	-152.24%	-1512.51%	-2234986.20%
Profit Margin	-160.35%	-226.01%	-146.02%	-1518.44%	-2235169.17%
EBITDA	-17.93	-16.87	-17.08	-19.35	-13.11
EBITDA Margin	-165.20%	-236.70%	-152.13%	-	-
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01
EBIT	-17.94	-16.88	-17.1	-19.36	-13.12
EBIT Margin	-165.31%	-236.86%	-152.24%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.